ApoC-III is the current target for a new class of drugs aimed at lowering triglyceride levels and indirectly preventing cardiovascular incidents and pancreatitis episodes in patients with hypertriglyceridemia. This evidence concerns the gene APOC3 and hypertriglyceridemia.